Benlysta's Modest Benefit vs. Risks Poses Dilemma - BioWorld Online

KIDK

Benlysta's Modest Benefit vs. Risks Poses Dilemma BioWorld Online Regulators also noted that patients with serious systemic lupus erythematosus (SLE) manifestations, such as renal and central nervous system (CNS) lupus, ... Barclays PLC (NYSE: BCS) Boosts Price Target on Human Genome (NASDAQ: HGSI)American Banking News FDA Questions Safety, Efficacy of BelimumabMedPage Today FDA staff critiques Human Genome Sciences' BenlystaBizjournals.com all 222 news articles »

Systemic Lupus Erythematosus - Market Forecasts to 2017 Now Available at ... - SBWire (press release)

Systemic Lupus Erythematosus - Market Forecasts to 2017 Now Available at ... SBWire (press release) GlobalData, the industry analysis specialist's new report, “Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017” is an essential ...

Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive ... - MarketWatch (press release)

Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive ... MarketWatch (press release) "While medical advances have improved the lives and survival of people with lupus, effective therapeutic options remain limited. ... Epratuzumab Effective in Systemic Lupus ErythematosusMedscape all 24 news articles »

UCB/Immunomedics's lupus drug excites researchers - Pharma Times

UCB/Immunomedics's lupus drug excites researchers Pharma Times ... a new humanised IgG1 monoclonal antibody in development by UCB and Immunomedics for systemic lupus erythematosus, have impressed investigators. ... Epratuzumab a new drug in development for SLE shows promising results in ...PharmiWeb.com (press release) all 2 news articles »